GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HLB Pharmaceutical Co 047920.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

7,220

-4.62%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About HLB Pharmaceutical Co

Its shares trade on KOSDAQ under the ticker 047920.KQ. It has been listed since 21 December 2015. In the fiscal year to 31 December 2025, it reported revenue of ₩205.58bn and net income of ₩4.57bn. At that date it held total assets of ₩170.68bn and shareholders' equity of ₩125.15bn.

HLB Pharmaceutical Co., Ltd. manufactures pharmaceuticals and related products based on biotechnology. The company is headquartered in Namyangju, Gyeonggi-Do. The company went IPO on 2015-12-21. The firm mainly manufactures and sells pharmaceutical products including cimetidine tablets, rozatin tablets, rabeprazole tablets, rozatinplus tablets, mosapia tablets and other ethical the counter (ETC) drugs; gynobetadine vaginal suppositories, and other over the counter (OTC) drugs; aceclofenac tablets, revotec tablets and other commissioned ETC drugs; L-carnitine tablets, elcatan tablets, hepatine liquids and other commissioned OTC drugs.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Dec 2015
Employees
230

Leadership

Pay as last reported

  • Jae Hyeong ParkChief Executive Officer, Director, since 2020
  • Yong Dong ChoManaging Director
  • Jong Bin KimManaging Director
  • Dong Yeop LeeAssistant Managing Director
  • Mr. Jae Hyeon NohInternal Auditor
  • Jeong Bok YooAssistant Managing Director
  • Yeong Dae JeonDirector
  • Dae Hyeon SonDirector
  • Jeong Yin YoonDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • HLB Pharmaceutical manufactures cimetidine tablets and rozatin tablets for ethical markets.
  • The firm produces gynobetadine vaginal suppositories and other over the counter drugs.
  • HLB Pharmaceutical employs 230 full-time staff in its Namyangju operations.

Weaknesses

  • The company relies on commissioned ETC drugs like aceclofenac tablets.
  • HLB Pharmaceutical sells rozatinplus tablets alongside other standard ethical products.
  • The firm manufactures L-carnitine tablets and elcatan tablets for commissioned clients.

Opportunities

  • HLB Pharmaceutical can expand its production of hepatine liquids for health.
  • The firm may grow its sales of mosapia tablets globally.
  • HLB Pharmaceutical could increase revenue from rozatin tablets in new markets.

Threats

  • Competition exists for cimetidine tablets in the pharmaceutical sector.
  • Regulatory changes may impact the sale of gynobetadine vaginal suppositories.
  • Market shifts could affect the demand for aceclofenac tablets significantly.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.